scholarly journals Statistical Validation Framework for Automotive Vehicle Simulations Using Uncertainty Learning

2021 ◽  
Vol 11 (5) ◽  
pp. 1983
Author(s):  
Benedikt Danquah ◽  
Stefan Riedmaier ◽  
Yasin Meral ◽  
Markus Lienkamp

The modelling and simulation process in the automotive domain is transforming. Increasing system complexity and variant diversity, especially in new electric powertrain systems, lead to complex, modular simulations that depend on virtual vehicle development, testing and approval. Consequently, the emerging key requirements for automotive validation involve a precise reliability quantification across a large application domain. Validation is unable to meet these requirements because its results provide little information, uncertainties are neglected, the model reliability cannot be easily extrapolated and the resulting application domain is small. In order to address these insufficiencies, this paper develops a statistical validation framework for dynamic systems with changing parameter configurations, thus enabling a flexible validation of complex total vehicle simulations including powertrain modelling. It uses non-deterministic models to consider input uncertainties, applies uncertainty learning to predict inherent model uncertainties and enables precise reliability quantification of arbitrary system parameter configurations to form a large application domain. The paper explains the framework with real-world data from a prototype electric vehicle on a dynamometer, validates it with additional tests and compares it to conventional validation methods. It is published as an open-source document. With the validation information from the framework and the knowledge deduced from the real-world problem, the paper solves its key requirements and offers recommendations on how to efficiently revise models with the framework’s validation results.

2016 ◽  
Vol 22 ◽  
pp. 219
Author(s):  
Roberto Salvatori ◽  
Olga Gambetti ◽  
Whitney Woodmansee ◽  
David Cox ◽  
Beloo Mirakhur ◽  
...  

VASA ◽  
2019 ◽  
Vol 48 (2) ◽  
pp. 134-147 ◽  
Author(s):  
Mirko Hirschl ◽  
Michael Kundi

Abstract. Background: In randomized controlled trials (RCTs) direct acting oral anticoagulants (DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists (VKAs) for patients with nonvalvular atrial fibrillation. Patients enrolled in such studies do not necessarily reflect the whole target population treated in real-world practice. Materials and methods: By a systematic literature search, 88 studies including 3,351,628 patients providing over 2.9 million patient-years of follow-up were identified. Hazard ratios and event-rates for the main efficacy and safety outcomes were extracted and the results for DOACs and VKAs combined by network meta-analysis. In addition, meta-regression was performed to identify factors responsible for heterogeneity across studies. Results: For stroke and systemic embolism as well as for major bleeding and intracranial bleeding real-world studies gave virtually the same result as RCTs with higher efficacy and lower major bleeding risk (for dabigatran and apixaban) and lower risk of intracranial bleeding (all DOACs) compared to VKAs. Results for gastrointestinal bleeding were consistently better for DOACs and hazard ratios of myocardial infarction were significantly lower in real-world for dabigatran and apixaban compared to RCTs. By a ranking analysis we found that apixaban is the safest anticoagulant drug, while rivaroxaban closely followed by dabigatran are the most efficacious. Risk of bias and heterogeneity was assessed and had little impact on the overall results. Analysis of effect modification could guide the clinical decision as no single DOAC was superior/inferior to the others under all conditions. Conclusions: DOACs were at least as efficacious as VKAs. In terms of safety endpoints, DOACs performed better under real-world conditions than in RCTs. The current real-world data showed that differences in efficacy and safety, despite generally low event rates, exist between DOACs. Knowledge about these differences in performance can contribute to a more personalized medicine.


2020 ◽  
Author(s):  
Jersy Cardenas ◽  
Gomez Nancy Sanchez ◽  
Sierra Poyatos Roberto Miguel ◽  
Luca Bogdana Luiza ◽  
Mostoles Naiara Modroño ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 209-OR
Author(s):  
SHWETA GOPALAKRISHNAN ◽  
PRATIK AGRAWAL ◽  
MICHAEL STONE ◽  
CATHERINE FOGEL ◽  
SCOTT W. LEE

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 994-P
Author(s):  
PRATIK AGRAWAL ◽  
MICHAEL STONE ◽  
SHWETA GOPALAKRISHNAN ◽  
CATHERINE FOGEL ◽  
SCOTT W. LEE ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document